Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of “Hold” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has earned an average rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $4.75.

Several research analysts recently commented on IPSC shares. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Mizuho started coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price target on the stock.

Century Therapeutics Stock Performance

NASDAQ IPSC opened at $2.03 on Monday. Century Therapeutics has a 52 week low of $0.44 and a 52 week high of $3.04. The stock’s 50 day moving average price is $2.16 and its two-hundred day moving average price is $2.22. The stock has a market capitalization of $367.58 million, a price-to-earnings ratio of -2.18 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, equities research analysts forecast that Century Therapeutics will post -0.47 EPS for the current year.

Institutional Trading of Century Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in Century Therapeutics during the first quarter worth $9,826,000. Commodore Capital LP bought a new stake in Century Therapeutics during the first quarter worth $19,652,000. Rock Springs Capital Management LP acquired a new stake in Century Therapeutics in the first quarter valued at $2,948,000. Versant Venture Management LLC acquired a new stake in Century Therapeutics in the first quarter valued at $27,495,000. Finally, DV Trading LLC bought a new position in shares of Century Therapeutics in the 1st quarter valued at about $3,164,000. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.